Cryptococcus neoformans as a model for radioimmunotherapy of infections

Ekaterina Dadachova, Arturo Casadevall

Research output: Contribution to journalReview articlepeer-review

Abstract

There is an obvious and urgent need for novel approaches to treat infectious diseases. The use of monoclonal antibodies in therapy of infectious diseases is now experiencing renewed interest. During the last 5 years radioimmunotherapy (RIT), a modality previously developed only for cancer treatment, has been successfully adapted for the treatment of experimental fungal, bacterial, and viral infections. As our model organism for studying the efficacy, mechanisms, potential toxicity, and radioresistance to RIT, as well as for comparison of RIT with the existing antimicrobial therapies we have chosen the encapsulated yeast Cryptococcus neoformans (CN). The success of RIT approach in laboratory studies provides encouragement for feasibility of therapeutically targeting microbes with labeled antibodies. In addition, the creation of "panantibodies" for RIT which would recognize antigens shared by the whole class of pathogens such as fungi, for example, would facilitate the introduction of RIT into the clinic.

Original languageEnglish (US)
Article number830286
JournalInterdisciplinary Perspectives on Infectious Diseases
Volume2011
DOIs
StatePublished - 2011

ASJC Scopus subject areas

  • Parasitology
  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology

Fingerprint Dive into the research topics of 'Cryptococcus neoformans as a model for radioimmunotherapy of infections'. Together they form a unique fingerprint.

Cite this